Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets
Related Experiment Video
Updated: Aug 5, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Angelo Silverio1, Francesco Paolo Cancro1, Luca Esposito1
1Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Baronissi, Italy.
Insights
Identifying novel risk factors like Lipoprotein(a) and targeting inflammation and gut dysbiosis are crucial for preventing recurrent ischemic events after acute coronary syndrome (ACS). Precision medicine approaches are key for optimizing secondary prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Preventive Cardiology
- Precision Medicine
Background:
- Secondary prevention after acute coronary syndrome (ACS) relies on risk factor control, healthy lifestyles, and antithrombotic therapy.
- Many patients experience recurrent ischemic events despite optimal traditional risk factor management and advanced therapies.
- Novel risk factors and therapeutic targets are essential for improving secondary prevention strategies post-ACS.
Purpose of the Study:
- To highlight emerging risk factors and therapeutic targets for secondary prevention in acute coronary syndrome (ACS) patients.
- To explore the role of Lipoprotein(a), inflammation, and gut dysbiosis in cardiovascular disease progression.
- To emphasize the potential of precision medicine in tailoring preventive strategies.
Main Methods:
- Review of current evidence on traditional and novel risk factors for recurrent ischemic events post-ACS.
- Analysis of emerging therapeutic strategies targeting Lipoprotein(a), inflammatory pathways (inflammasome), and the gut microbiome.
- Discussion of the role of precision medicine in personalized cardiovascular risk management.
Main Results:
- Lipoprotein(a) (Lp(a)) is identified as an independent predictor of adverse events post-ACS, with novel therapies showing promise in reducing its levels.
- Targeting inflammatory pathways, including the inflammasome and cytokines, has demonstrated potential in reducing cardiovascular events in post-ACS patients.
- Preliminary evidence suggests a role for gut dysbiosis in cardiovascular disease, indicating potential therapeutic avenues through microbiome modulation.
Conclusions:
- Novel targets such as Lp(a), inflammation, and gut dysbiosis offer new opportunities for secondary prevention after ACS.
- Emerging therapies targeting these factors, alongside precision medicine approaches, are vital for optimizing patient outcomes.
- Further research, including large-scale studies, is needed to confirm the role of these novel factors and refine targeted interventions.
Abstract:
The control of cardiovascular risk factors, the promotion of a healthy lifestyle, and antithrombotic therapy are the cornerstones of secondary prevention after acute coronary syndrome (ACS). However, many patients have recurrent ischemic events despite the optimal control of traditional modifiable risk factors and the use of tailored pharmacological therapy, including new-generation antiplatelet and lipid-lowering agents. This evidence emphasizes the importance of identifying novel risk factors and targets to optimize secondary preventive strategies. Lipoprotein(a) (Lp(a)) has emerged as an independent predictor of adverse events after ACS. New molecules such as anti-PCSK9 monoclonal antibodies, small interfering RNAs, and antisense oligonucleotides can reduce plasma Lp(a) levels and are associated with a long-term outcome benefit after the index event. The inflammatory stimulus and the inflammasome, pivotal elements in the development and progression of atherosclerosis, have been widely investigated in patients with coronary artery disease. More recently, randomized clinical trials including post-ACS patients treated with colchicine and monoclonal antibodies targeting cytokines yielded promising results in the reduction in major cardiovascular events after an ACS. Gut dysbiosis has also raised great interest for its potential pathophysiological role in cardiovascular disease. This evidence, albeit preliminary and needing confirmation by larger population-based studies, suggests the possibility of targeting the gut microbiome in particularly high-risk populations. The risk of recurrent ischemic events after ACS is related to the complex interaction between intrinsic predisposing factors and environmental triggers. The identification of novel risk factors and targets is fundamental to customizing patient clinical management with a precision medicine perspective.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction